Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma

NCT03631836 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Monoclonal antibody
DRUG: Bevacizumab
BIOLOGICAL: Blood sample
DEVICE: Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)

Sponsor

Assistance Publique Hopitaux De Marseille